Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Accenture
UBS
Julphar
Healthtrust
Teva

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 10,377,824

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,377,824
Title:Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
Inventor(s): Lonberg; Nils (Woodside, CA), Srinivasan; Mohan (Cupertino, CA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:16/125,028
Patent Claims:see list of patent claims

Details for Patent 10,377,824

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2032-07-02 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 001 2015-03-04 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2032-07-02 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 002 2015-03-04 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2032-07-02 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125554 001 2015-11-23 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2032-07-02 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
QuintilesIMS
Johnson and Johnson
Daiichi Sankyo
Chubb
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.